{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"12.9","value":"5.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive pomalidomide PO QD on days 1-21 and dexamethasone PO QD on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may cross over to Arm II.","id":"OG000","title":"Arm I (Pomalidomide, Dexamethasone)"}],"paramType":"MEDIAN","populationDescription":"Arm 1 patients that chose to crossover to Arm 2 treatment (add IXA treatment).","reportingStatus":"POSTED","timeFrame":"Up to 3 years post-registration (at crossover)","title":"Progression Free Survival (PFS) for All Patients on the Pomalidomide/Dexamethasone Arm at the Time of Cross-over to Pomalidomide/Dexamethasone/Ixazomib (Phase II)","type":"SECONDARY","unitOfMeasure":"months"}